Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children |
Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD |
Reach Grants |
2018 |
Washington |
Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations |
The Regents of the University of Michigan / Jolanta Grembecka, PhD |
Reach Grants |
2022 |
Michigan |
LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma |
University of Virginia, School of Medicine / Michael Engel, MD/PhD |
Reach Grants |
2016 |
Virginia |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |
Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma
|
Duke University Medical Center / Gerard Blobe, MD, PhD |
Reach Grants |
2013 |
North Carolina |
Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma
|
Beckman Research Institute of City of Hope / Margarita Gutova, MD |
Reach Grants |
2013 |
California |
Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen |
Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. |
Reach Grants |
2014 |
New York |
Moving EphB4 Therapeutics to Pediatric Phase I/II Trials |
Oregon Health & Science University / Charles Keller, MD |
Reach Grants |
2013 |
Oregon |
Combining Oncolytic Vaccinia Virus with GD2.CAR-modified Vaccinia Virus-specific T-cells for the Treatment of Relapsed Neuroblastoma and Sarcoma |
Baylor College of Medicine / Cliona Rooney, PhD |
Reach Grants |
2013 |
Texas |
Targeting Novel Pediatric-Specific FLT3 Mutations |
Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD,PhD |
Reach Grants |
2015 |
Washington |